Literature DB >> 31634456

Humanized mouse models of genetic immune disorders and hematological malignancies.

Rajeev K Tyagi1, Jing Li2, Justin Jacobse3, Scott B Snapper4, Dror S Shouval5, Jeremy A Goettel6.   

Abstract

The immune system is quite remarkable having both the ability to tolerate innocuous and self-antigens while possessing a robust capacity to recognize and eradicate infectious pathogens and foreign entities. The genetics that encode this delicate balancing act include multiple genes and specialized cell types. Over the past several years, whole exome and whole genome sequencing has uncovered the genetics driving many human immune-mediated diseases including monogenic disorders and hematological malignancies. With the advent of genome editing technologies, the ability to correct genetic immune defects in autologous cells holds great promise for a number of conditions. Since assessment of novel therapeutic strategies have been difficult in mice, in recent years, immunodeficient mice capable of engrafting human cells and tissue have been developed and utilized for a variety of research applications. In this review, we discuss immune-humanized mice as a research tool to study human immunobiology and genetic immune disorders in vivo and the promise of future applications.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Humanized; Immune; Immunotherapy; Monogenic; Mouse

Mesh:

Year:  2019        PMID: 31634456      PMCID: PMC7050416          DOI: 10.1016/j.bcp.2019.113671

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  114 in total

Review 1.  Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse scid gene.

Authors:  P A Jeggo; S P Jackson; G E Taccioli
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

2.  Genome-edited baby claim provokes international outcry.

Authors:  David Cyranoski; Heidi Ledford
Journal:  Nature       Date:  2018-11       Impact factor: 49.962

Review 3.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

6.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

Review 7.  Ovarian tissue xenografting.

Authors:  Y Aubard
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2003-05-01       Impact factor: 2.435

8.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

9.  NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

Authors:  F E Nicolini; J D Cashman; D E Hogge; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

10.  Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein.

Authors:  Laura Chiossone; Sandra Audonnet; Bruno Chetaille; Lionel Chasson; Catherine Farnarier; Yael Berda-Haddad; Stefan Jordan; Ulrich H Koszinowski; Marc Dalod; Karin Mazodier; Daniela Novick; Charles A Dinarello; Eric Vivier; Gilles Kaplanski
Journal:  Front Immunol       Date:  2012-08-08       Impact factor: 7.561

View more
  1 in total

1.  Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.

Authors:  Juan A Marín-Jiménez; Anna Capasso; Matthew S Lewis; Stacey M Bagby; Sarah J Hartman; Jeremy Shulman; Natalie M Navarro; Hui Yu; Chris J Rivard; Xiaoguang Wang; Jessica C Barkow; Degui Geng; Adwitiya Kar; Ashley Yingst; Dejene M Tufa; James T Dolan; Patrick J Blatchford; Brian M Freed; Raul M Torres; Eduardo Davila; Jill E Slansky; Roberta Pelanda; S Gail Eckhardt; Wells A Messersmith; Jennifer R Diamond; Christopher H Lieu; Michael R Verneris; Jing H Wang; Katja Kiseljak-Vassiliades; Todd M Pitts; Julie Lang
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.